Supplementary Figure 6 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling | Synapse
March 11, 2024Open Access
Supplementary Figure 6 from Antibody–Drug Conjugate αEGFR-E-P125A Reduces Triple-negative Breast Cancer Vasculogenic Mimicry, Motility, and Metastasis through Inhibition of EGFR, Integrin, and FAK/STAT3 Signaling
Key Points
Key points are not available for this paper at this time.
Abstract
Effects of α5β1 integrin and its downstream signaling components on VM tube formation